Atovaquone and proguanil for the treatment of malaria in Brazil

The Journal of Infectious Diseases
F E de AlencarL Pang

Abstract

The purpose of this study was to compare an experimental regimen of atovaquone plus proguanil with the standard regimen of quinine plus tetracycline for the treatment of uncomplicated falciparum malaria. The study was designed as an open, randomized study of men presenting with symptoms of uncomplicated malaria and thick-smear slide confirmation of parasitemia (1000-100,000 ring forms/microL). Subjects were hospitalized for 28 days to insure medication compliance and to rule out the possibility of reinfections. With 77 patients in each group, the cure rates were 98.7% and 100% for atovaquone plus proguanil and quinine plus tetracycline, respectively. The parasite clearance times (mean, 56 h) and fever clearance times (mean, 19 h) were significantly shorter in the atovaquone plus proguanil group, and there were significantly fewer side effects in the atovaquone plus proguanil group. Atovaquone plus proguanil is an efficacious, easily administered, safe regimen for the treatment of uncomplicated, multidrug-resistant falciparum malaria in Brazil.

Citations

Feb 21, 2002·Current Infectious Disease Reports·Lin H. Chen, Mary E. Wilson
Jul 18, 2000·Transactions of the Royal Society of Tropical Medicine and Hygiene·M O FonsecaM Boulos
Oct 9, 1998·Transactions of the Royal Society of Tropical Medicine and Hygiene·A SabchareonD B Hutchinson
May 18, 1999·Transactions of the Royal Society of Tropical Medicine and Hygiene·J D Chulay
Mar 16, 2000·Transactions of the Royal Society of Tropical Medicine and Hygiene·S LooareesuwanJ D Chulay
Oct 17, 2003·The New England Journal of Medicine·Eli SchwartzMartin Cetron
Nov 14, 2003·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Steffen BorrmannPeter G Kremsner
Jun 8, 2006·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Lynn W KitchenDonald R Skillman
Apr 18, 2002·Antimicrobial Agents and Chemotherapy·Aaron L Baggish, David R Hill
Jul 18, 2002·Antimicrobial Agents and Chemotherapy·K Jones, S A Ward
Jul 5, 2005·Expert Opinion on Investigational Drugs·P Winstanley, P Olliaro
Nov 24, 1999·Mayo Clinic Proceedings·J E Rosenblatt
Nov 17, 2006·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·Akihiro HitaniMikio Kimura
Feb 28, 2006·The Lancet Infectious Diseases·Carlos Franco-Paredes, José Ignacio Santos-Preciado
Jul 11, 1998·Infectious Disease Clinics of North America·K C Kain, J S Keystone
Aug 19, 2003·The Annals of Pharmacotherapy·Fawziah MarraMary H H Ensom
Apr 14, 2016·The American Journal of Tropical Medicine and Hygiene·Simone Ladeia-AndradeMarcelo U Ferreira
Dec 14, 2017·The Journal of Antimicrobial Chemotherapy·Henry M StainesSanjeev Krishna
Oct 20, 2005·The Cochrane Database of Systematic Reviews·A Osei-AkotoS P O Owusu-Ofori
Nov 26, 2005·Expert Review of Anti-infective Therapy·Samir N Patel, Kevin C Kain
Mar 1, 2005·Pharmacological Reviews·Aric Gregson, Christopher V Plowe
Aug 23, 2002·The Pediatric Infectious Disease Journal·Paul S Sehdev
May 22, 2016·Malaria Journal·Marcelo U Ferreira, Marcia C Castro
Jan 19, 2021·The Cochrane Database of Systematic Reviews·Andrew Blanshard, Paul Hine

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimalarial Agents

Antimalarial agents, also known as antimalarials, are designed to prevent or cure malaria. Discover the latest research on antimalarial agents here.

Antimalarial Agents (ASM)

Antimalarial agents, also known as antimalarials, are designed to prevent or cure malaria. Discover the latest research on antimalarial agents here.